600276 恒瑞医药
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入20,189,30418.67%22,819,78521,275,27125,905,52627,734,599
减:营业总成本15,089,97913.81%18,214,15317,747,08421,792,96921,282,046
    其中:营业成本2,833,1836.61%3,525,2483,486,6393,741,7993,348,690
               财务费用(447,888)20.58%(478,390)(470,867)(337,956)(181,744)
               资产减值损失9,250-172.78%(107,217)(146,684)(13,861)(7,278)
公允价值变动收益9,530-126.64%(58,257)76,50336,23316,497
投资收益(31,420)171.67%(49,157)387,365213,434341,425
    其中:对联营企业和合营企业的投资收益(54,228)15.10%(72,696)(62,996)(6,940)--
营业利润5,345,29135.62%4,909,9054,111,9604,664,8167,007,072
利润总额5,086,74033.43%4,667,1103,968,4924,466,3096,895,480
减:所得税费用470,41030.18%389,289153,351(17,718)586,587
净利润4,616,33033.77%4,277,8213,815,1424,484,0276,308,893
减:非控股权益(3,246)-85.73%(24,615)(91,233)(46,191)(19,490)
股东净利润4,619,57632.98%4,302,4363,906,3754,530,2186,328,383

市场价值指针
每股收益 (元) *0.73032.73%0.6800.6100.7100.990
每股派息 (元) *----0.2000.1600.1600.200
每股净资产 (元) *6.86110.42%6.3445.9295.4735.721
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容